Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal.
Katz
Kenneth A
KA
D000077944:Alefacept; D002986:Clinical Trials as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D019233:Retreatment; D012720:Severity of Illness Index
D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept; D008727:Methotrexate